Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
AngioGenex Inc is a United States-based biopharmaceutical company. It is dedicated to the development and commercialization of a novel, inexpensive treatment for vascular diseases including many forms of cancer and macular degeneration. Its lead drug candidates include AGX51 and several other proprietary small molecules that have shown specific activity in various animal models of various cancers and macular degeneration. Further, it also focuses on developing Id-inhibitor drugs to treat cancer and macular degeneration. Geographically, the activities are carried out through the region of the United States.
New York, NY, 10017